Monitor Biogen's integration of Amicus' commercial operations and upcoming Q1 earnings call for updated 2026 guidance. The acquisition significantly expands Biogen's rare disease portfolio with two commercial products, potentially driving revenue growth, but increases leverage that will need to be managed.
BMRN drugs
BMRN drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 27 $53.62entry
- T+1 · 7mo ago −0.63%α −0.15% · $53.28
- T+5 · 7mo ago +3.36%α +2.96% · $55.42
- T+20 · 6mo ago −1.39%α −6.34% · $52.88
- T+60 · 4mo ago +8.91%α +4.40% · $58.40
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Biogen completed its acquisition of Amicus Therapeutics for $4.8 billion in an all-cash transaction, funding the deal through a $2.8 billion term loan package and previously issued notes. The acquisition adds Fabry and Pompe disease treatments to Biogen's portfolio, strengthening its rare disease focus.
Key Financial Metrics
Key Facts
- Completed acquisition of Amicus Therapeutics for $4.8 billion in all-cash transaction
- Acquired Galafold (Fabry disease) and Pombiliti + Opfolda (Pompe disease) treatments
- Financed through $2.0 billion Term Loan B, $800 million Term Loan A, and $850 million 2034 Notes
- Existing credit agreement was repaid and terminated
- New senior secured credit facilities have five- to seven-year maturities
Financial Impact
$4.8 billion acquisition funded by $2.8 billion in new term loans and existing capital
Risk Factors
- Integration challenges between the two companies
- Increased debt burden from the acquisition financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-179243 |
| Document: d113922d8k.htm | 0001193125-26-179243 |
| Document: d113922dex991.htm | 0001193125-26-179243 |
| Document: d113922dex41.htm | 0001193125-26-179243 |
| Document: 0001193125-26-179243-index-headers.html | 0001193125-26-179243 |
| Document: 0001193125-26-179243-index.html | 0001193125-26-179243 |
| Document: 0001193125-26-179243.txt | 0001193125-26-179243 |
Track record
16 reports on BMRN
1 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +3.49% at T+1 after the Aug 18, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 4, 202612d ago SC 13G/A Neutral 3/10 Entry $56.12 to $56.70 Now $57.99 +3.33% ▲ +1.03% −2.26% vs SPY
- Nov 2, 202614d ago 8-K Bearish 6/10 Entry $55.66 to $57.13 Now $57.99 −4.19% ▼ −2.64% −3.23% vs SPY
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $57.49 to $56.12 Now $57.99 +0.87% ▼ −2.38% +2.34% vs SPY
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $56.00 to $57.13 Now $57.99 +3.55% ▲ +2.02% +2.73% vs SPY
- Oct 6, 20265w ago 8-K Bearish 6/10 Entry $55.20 to $55.14 Now $57.99 −5.05% ▲ +0.11% −0.87% vs SPY
- Sep 15, 20268w ago 8-K Neutral 4/10 Entry $64.45 to $63.94 Now $57.99 −10.02% ▼ −0.79% −1.61% vs SPY
- Sep 14, 20269w ago 8-K Neutral 2/10 Entry $66.41 to $64.06 Now $57.99 −12.68% ▼ −3.54% −3.65% vs SPY
- Sep 1, 202610w ago 8-K Neutral 3/10 Entry $64.84 to $64.41 Now $57.99 −10.56% ▼ −0.66% −0.74% vs SPY
- Sep 1, 202610w ago Press Release Neutral 4/10 Entry $64.84 to $64.41 Now $57.99 −10.56% ▼ −0.66% −0.74% vs SPY
- Aug 31, 202611w ago 8-K Bullish 6/10 Entry $65.23 to $64.63 Now $57.99 −11.10% ▼ −0.92% −0.78% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers